Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96QD8

UPID:
S38A2_HUMAN

ALTERNATIVE NAMES:
Amino acid transporter A2; Protein 40-9-1; Solute carrier family 38 member 2; System A amino acid transporter 2; System A transporter 1; System N amino acid transporter 2

ALTERNATIVE UPACC:
Q96QD8; Q6IA88; Q6ZMG2; Q9HAV3; Q9NVA8; Q9P2G5

BACKGROUND:
The protein Sodium-coupled neutral amino acid symporter 2, known for its alternative names such as Amino acid transporter A2 and System A transporter 1, is pivotal in the cotransport of neutral amino acids and sodium ions. This symporter's activity is crucial for amino acid supply to the brain and fetus, supporting cognitive functions and prenatal development. It also plays a role in maintaining the glutamine/glutamate balance, essential for neurotransmission and bone health.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Sodium-coupled neutral amino acid symporter 2 offers a pathway to novel therapeutic approaches. Given its critical role in neurotransmitter regulation and nutrient transport, targeting this protein could lead to breakthroughs in treating mental health conditions and enhancing fetal development.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.